Exenatide promotes insulin release, increasing hypoglycemia risk when combined with insulin secretagogues. Dose reduction of secretagogue or insulin recommended.
Source: NLP:exenatide
Exenatide Interactions
Brand names: Byetta
GLP-1 Receptor Agonist · Glucagon-like Peptide-1 (GLP-1) Agonists
Route: Subcutaneous
Contraindications
4 CONTRAINDICATIONS BYETTA is contraindicated in patients with: • A prior severe hypersensitivity reaction to exenatide or to any of the excipients in BYETTA. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with BYETTA [see Warnings and Precautions (5.7) ]. • A history of drug-induced immune-mediated thrombocytopenia from exenatide products. Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported with exenatide use [see Warnings and Precautions (5.8) ] . • History of severe hypersensitivity to exenatide or any of the excipients in BYETTA. (4) • History of drug-induced immune-mediated thrombocytopenia from exenatide products. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Limited data with BYETTA in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations ). Based on animal reproduction studies, there may be risks to the fetus from exposure to BYETTA during pregnancy. BYETTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal reproduction studies identified increased adverse fetal and neonatal outcomes from exposure to exenatide during pregnancy and lactation in association with maternal effects. In mice, exenatide administered during gestation and lactation caused increased neonatal deaths at systemic exposure 3-times the human exposure resulting from the maximum recommended human dose (MRHD) of 20 mcg/day for BYETTA (see Data ) . The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with an HbA1c >7 and has been reported to be as high as 20-25% in women with HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryofetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Animal Data In studies evaluating reproduction and development in pregnant mice and rabbits, maternal animals were administered exenatide, the active ingredient in BYETTA, by subcutaneous injection twice a day. In pregnant mice given
4 interactions on record
Exenatide + AcetaminophenModerate
Exenatide slows gastric emptying, potentially reducing the rate of absorption of orally administered drugs like acetaminophen. Use caution with oral medications.
Source: NLP:exenatide
Exenatide + DigoxinModerate
Decreases digoxin concentrations. Requires monitoring and dose adjustment.
Source: NLP:digoxin
Exenatide + WarfarinModerate
Post-marketing reports of increased INR with exenatide use, sometimes associated with bleeding. Monitor prothrombin time more frequently after initiation or alteration of exenatide therapy.
Source: NLP:exenatide